Mavenclad Poised To Be Big Mover For Merck KGaA
Executive Summary
The German group is predicting sales of its new MS drug Mavenclad in the mid-triple digit million euro range worldwide in 2019 if all goes well across the Atlantic.
You may also be interested in...
Merck KGaA Plays Down Mavenclad Label And $99,500 annual Price For 10 MS Pills
Merck KGaA's multiple sclerosis pill Mavenclad has finally won FDA approval, but some analysts think its US label, stipulating second-line use in relapsing MS but not in patients with clinically isolated syndrome, may hurt its uptake there.
Merck KGaA Expects Core Franchises, Alliances To Strengthen In China
Merck KGaA's healthcare business in China will continue to center around its fertility, general medicines and endocrinology therapies while also building on new corporate alliances there, the German conglomerate’s global operations head told Scrip.
Keytruda/Inlyta Data Stoke Competition In Kidney Cancer
Competing combination therapies may soon be battling for attention as first-line therapies for advanced or metastatic renal cell carcinoma, with Merck & Co being the latest big pharma to release more data on the Keytruda/Inlyta combo in the setting.